Charles River Laboratories Announces Third-Quarter 2021 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Charles River Labs (CRL) PT Lowered to $464 at Jefferies
November 4, 2021 7:57 AM EDTJefferies analyst David Windley lowered the price target on Charles River Labs (NYSE: CRL) to $464.00 (from $480.00) while maintaining a Buy rating.
The analyst commented, "We are maintaining our Buy rating on 2 key factors: 1) we think demand is strong enough to support DD... More
Charles River Laboratories (CRL) Tops Q3 EPS by 12c, Updates Guidance
November 3, 2021 7:09 AM EDTCharles River Laboratories (NYSE: CRL) reported Q3 EPS of $2.70, $0.12 better than the analyst estimate of $2.58. Revenue for the quarter came in at $895.9 million versus the consensus estimate of $908.19 million.
GUIDANCE:
Charles River Laboratories sees FY2021 EPS of $10.20-$10.30, versus the consensus of... More
